CEBPB |
HepG2 (hepatoblastoma) |
low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder) |
Permissive
Robust
|
Homo sapiens |
ENCSR000EEX
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
day 0 of differentiation |
Permissive
Robust
|
Mus musculus |
GSE27826
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
2 hours of differentiation |
Permissive
Robust
|
Mus musculus |
GSE27826
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
4 hours of differentiation |
Permissive
Robust
|
Mus musculus |
GSE27826
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
day 2 of differentiation |
Permissive
Robust
|
Mus musculus |
GSE27826
...
|
MA0466.2
|
CEBPB |
dendritic cells |
LPS, 120 min |
Permissive
|
Mus musculus |
GSE36099
...
|
MA0466.2
|
CEBPB |
liver |
0 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
3 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
8 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
16 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
24 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
36 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
48 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
liver |
168 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0466.2
|
CEBPB |
dermal fibroblasts |
No treatment |
Permissive
Robust
|
Mus musculus |
GSE44942
...
|
MA0466.2
|
CEBPB |
dermal fibroblasts |
Thapsigargin treatment for 3 hrs |
Permissive
|
Mus musculus |
GSE44942
...
|
MA0466.2
|
CEBPB |
liver |
Ad-lib fed |
Permissive
Robust
|
Mus musculus |
GSE45674
...
|
MA0466.2
|
CEBPB |
liver |
dex adGFP |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0466.2
|
CEBPB |
liver |
dex adDN-C/EBP |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0466.2
|
CEBPB |
liver |
veh |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0466.2
|
CEBPB |
liver |
dex |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0466.2
|
CEBPB |
MC3T3-E1 (preosteoblasts) |
ethanol vehicle |
Permissive
Robust
|
Mus musculus |
GSE41920
...
|
MA0466.2
|
CEBPB |
MC3T3-E1 (preosteoblasts) |
ethanol vehicle |
Permissive
Robust
|
Mus musculus |
GSE41920
...
|
MA0466.2
|
CEBPB |
MC3T3-E1 (preosteoblasts) |
100nM 1,25(OH)2D3 |
Permissive
Robust
|
Mus musculus |
GSE51513
...
|
MA0466.2
|
CEBPB |
MC3T3-E1 (preosteoblasts) |
100nM 1,25(OH)2D3 |
Permissive
Robust
|
Mus musculus |
GSE51513
...
|
MA0466.2
|
CEBPB |
BV-2 (brain microglial cells) |
wt human Htt overexpression |
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0466.2
|
CEBPB |
BV-2 (brain microglial cells) |
mutant human Htt overexpression |
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0466.2
|
CEBPB |
C10 (pre-B-cells) |
0.1% ethanol as control sample |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0466.2
|
CEBPB |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0466.2
|
CEBPB |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0466.2
|
CEBPB |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0466.2
|
CEBPB |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0466.2
|
CEBPB |
liver |
none |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0466.2
|
CEBPB |
liver |
none |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0466.2
|
CEBPB |
liver |
prednisolone |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0466.2
|
CEBPB |
embryonic stem cell-derived hemangioblasts |
none |
Permissive
Robust
|
Mus musculus |
GSE69099
...
|
MA0466.2
|
CEBPB |
embryonic stem cell-derived hemogenic endothelium |
none |
Permissive
|
Mus musculus |
GSE69099
...
|
MA0466.2
|
CEBPB |
embryonic stem cell-derived hematopoietic progenitors |
none |
Permissive
Robust
|
Mus musculus |
GSE69099
...
|
MA0466.2
|
CEBPB |
embryonic stem cell-derived macrophages |
none |
Permissive
Robust
|
Mus musculus |
GSE69099
...
|
MA0466.2
|
CEBPB |
embryonic stem cell-derived mesoderm |
none |
Permissive
Robust
|
Mus musculus |
GSE69099
...
|
MA0466.2
|
CEBPB |
liver |
FoxA1 and FoxA2 KO |
Permissive
Robust
|
Mus musculus |
GSE77670
...
|
MA0466.2
|
CEBPB |
bone marrow-derived mesenchymal stem cells |
osteogenic media day 7 |
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0466.2
|
CEBPB |
bone marrow-derived mesenchymal stem cells |
osteogenic media day 15 |
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0466.2
|
CEBPB |
bone marrow-derived mesenchymal stem cells |
adipose media day 7 |
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0466.2
|
CEBPB |
hepatocytes |
fed 10 h |
Permissive
Robust
|
Mus musculus |
GSE72084
...
|
MA0466.2
|
CEBPB |
hepatocytes |
fasted 24 h |
Permissive
Robust
|
Mus musculus |
GSE72084
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0466.2
|
CEBPB |
brown adipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0466.2
|
CEBPB |
brown adipocytes |
day0 |
Permissive
|
Mus musculus |
GSE83757
...
|
MA0466.2
|
CEBPB |
brown adipocytes |
day6 |
Permissive
Robust
|
Mus musculus |
GSE83757
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
Vehicle |
Permissive
Robust
|
Mus musculus |
GSE85100
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
CEBPB mutated; Vehicle |
Permissive
Robust
|
Mus musculus |
GSE85100
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
Doxycycline |
Permissive
Robust
|
Mus musculus |
GSE85100
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
CEBPB mutated;Doxycycline |
Permissive
Robust
|
Mus musculus |
GSE85100
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
Doxycycline + BYK204165 |
Permissive
Robust
|
Mus musculus |
GSE85100
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
IFNg (100 ng/ml) for 4hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
IFNg (100 ng/ml) and IL4 (10ng/ml) for 4hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0466.2
|
CEBPB |
SUM159PT (Triple negative breast cancer) |
DMSO |
Permissive
Robust
|
Homo sapiens |
GSE87418
...
|
MA0466.2
|
CEBPB |
SUM159PT (Triple negative breast cancer) |
100nM trametinib |
Permissive
Robust
|
Homo sapiens |
GSE87418
...
|
MA0466.2
|
CEBPB |
SUM159PT (Triple negative breast cancer) |
300nM JQ1 |
Permissive
Robust
|
Homo sapiens |
GSE87418
...
|
MA0466.2
|
CEBPB |
SUM159PT (Triple negative breast cancer) |
100nM trametinib, 300nM JQ1 |
Permissive
Robust
|
Homo sapiens |
GSE87418
...
|
MA0466.2
|
CEBPB |
monocyte-derived macrophages |
IFN-gamma |
Permissive
Robust
|
Homo sapiens |
GSE98367
...
|
MA0466.2
|
CEBPB |
monocyte-derived macrophages |
none |
Permissive
Robust
|
Homo sapiens |
GSE98367
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
lipid A 0 min |
Permissive
Robust
|
Mus musculus |
GSE99895
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
lipid A 15 min |
Permissive
Robust
|
Mus musculus |
GSE99895
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
lipid A 30 min |
Permissive
Robust
|
Mus musculus |
GSE99895
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
lipid A 60 min |
Permissive
Robust
|
Mus musculus |
GSE99895
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
lipid A 120 min |
Permissive
Robust
|
Mus musculus |
GSE99895
...
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 5 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR752AQK
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 30 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR447ZMS
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 4 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR606ZTC
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 8 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR474DCX
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 3 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR216GEB
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 7 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR853DWE
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 12 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR269IUA
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 2 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR182OZC
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 10 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR190VMK
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR299ILN
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 6 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR375BUB
|
MA0466.2
|
CEBPB |
OCI-AML3 |
Control No Treatment |
Permissive
Robust
|
Homo sapiens |
GSE104745
...
|
MA0466.2
|
CEBPB |
OCI-AML3 |
JQ1, 500 nM for 24 h |
Permissive
Robust
|
Homo sapiens |
GSE104745
...
|
MA0466.2
|
CEBPB |
THP-1 (acute monocytic leukemia) |
Treatment: untreated, eGFP(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0466.2
|
CEBPB |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0466.2
|
CEBPB |
THP-1 (acute monocytic leukemia) |
Treatment: untreated, IAV NS1(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0466.2
|
CEBPB |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0466.2
|
CEBPB |
HEE (human epididymis epithelial cells) |
Treatment: without treatment of R1881 (methyltrienolone) |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0466.2
|
CEBPB |
HEE (human epididymis epithelial cells) |
Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0466.2
|
CEBPB |
HEE (human epididymis epithelial cells) |
Treatment: without treatment of R1881 (methyltrienolone) |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0466.2
|
CEBPB |
HEE (human epididymis epithelial cells) |
Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0466.2
|
CEBPB |
iBAd |
Genotype: IL10Ra-Expressing Strain: C57/Bl6 Source: D5 differentiated cells Treatment: untreated |
Permissive
Robust
|
Mus musculus |
GSE111208
...
|
MA0466.2
|
CEBPB |
iBAd |
Genotype: IL10Ra-Expressing Strain: C57/Bl6 Source: D5 differentiated cells Treatment: treated with IL10 |
Permissive
Robust
|
Mus musculus |
GSE111208
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
KLA 1h; SPRET/EiJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
SPRET/EiJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
KLA 1h; PWK/PhJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
PWK/PhJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
KLA 1h; NOD/ShiLtJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
NOD/ShiLtJ strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
KLA 1h; C57BL/6J strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
C57BL/6J strain |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
KLA 1h; BALB/cJ |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
BMDM (bone marrow-derived macrophages) |
BALB/cJ |
Permissive
Robust
|
Mus musculus |
GSE109965
...
|
MA0466.2
|
CEBPB |
primary hepatocytes |
Strain: C57BL/6 Source: primary mouse hepatocytes Treatment: IL-1b (10ng/ml) for 2 hr |
Permissive
Robust
|
Mus musculus |
GSE96767
...
|
MA0466.2
|
CEBPB |
mpkCCD (clone 11) |
Treatment: vehicle treatment Cell type: cultured mouse cortical collecting duct cells (mpkCCD) Passage: 6 to 12 |
Permissive
Robust
|
Mus musculus |
GSE98076
...
|
MA0466.2
|
CEBPB |
mpkCCD (clone 11) |
Treatment: vehicle treatment Cell type: cultured mouse cortical collecting duct cells (mpkCCD) Passage: 6 to 12 |
Permissive
Robust
|
Mus musculus |
GSE98076
...
|
MA0466.2
|
CEBPB |
mpkCCD (clone 11) |
Treatment: 0.1 nM dDAVP treatment Cell type: cultured mouse cortical collecting duct cells (mpkCCD) Passage: 6 to 12 |
Permissive
Robust
|
Mus musculus |
GSE98076
...
|
MA0466.2
|
CEBPB |
mpkCCD (clone 11) |
Treatment: 0.1 nM dDAVP treatment Cell type: cultured mouse cortical collecting duct cells (mpkCCD) Passage: 6 to 12 |
Permissive
Robust
|
Mus musculus |
GSE98076
...
|
MA0466.2
|
CEBPB |
JB6 (Human anaplastic large cell lymphoma) |
Treatment: DMSO for 3 hrs |
Permissive
Robust
|
Homo sapiens |
GSE117164
...
|
MA0466.2
|
CEBPB |
JB6 (Human anaplastic large cell lymphoma) |
Treatment: 300 nM Crizotinib for 3 hrs |
Permissive
Robust
|
Homo sapiens |
GSE117164
...
|
MA0466.2
|
CEBPB |
SU-DHL-1 (Anaplastic large cell lymphoma) |
Treatment: DMSO for 3 hrs |
Permissive
Robust
|
Homo sapiens |
GSE117164
...
|
MA0466.2
|
CEBPB |
SU-DHL-1 (Anaplastic large cell lymphoma) |
Treatment: 300 nM Crizotinib for 3 hrs |
Permissive
Robust
|
Homo sapiens |
GSE117164
...
|
MA0466.2
|
CEBPB |
|
MACROPHAGE |
Permissive
Robust
|
Homo sapiens |
GSE31621
|
MA0466.2
|
CEBPB |
hFOB 1.19 (fetal osteoblast) |
DIFF |
Permissive
Robust
|
Homo sapiens |
GSE82295
|
MA0466.2
|
CEBPB |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BQI
|
MA0466.2
|
CEBPB |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BRQ
|
MA0466.2
|
CEBPB |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
|
Homo sapiens |
ENCSR000BRX
|
MA0466.2
|
CEBPB |
HCT-116 (colon carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BSD
|
MA0466.2
|
CEBPB |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BSR
|
MA0466.2
|
CEBPB |
Ishikawa (endometrial adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BTT
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BUB
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DYI
|
MA0466.2
|
CEBPB |
WA01 (H1, human embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EBV
|
MA0466.2
|
CEBPB |
HeLa S3 (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EDA
|
MA0466.2
|
CEBPB |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EEE
|
MA0466.2
|
CEBPB |
IMR90 (lung fibroblasts) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EFM
|
MA0466.2
|
CEBPB |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR681NOM
|
MA0466.2
|
CEBPB |
3T3-L1 (embryonic fibroblasts) |
|
Permissive
Robust
|
Mus musculus |
GSE21898
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE21898
...
|
MA0466.2
|
CEBPB |
peritoneal macrophages |
|
Permissive
Robust
|
Mus musculus |
GSE21314
...
|
MA0466.2
|
CEBPB |
myocytes |
|
Permissive
Robust
|
Mus musculus |
ENCSR000AIB
...
|
MA0466.2
|
CEBPB |
myocytes |
|
Permissive
Robust
|
Mus musculus |
ENCSR000AIB
...
|
MA0466.2
|
CEBPB |
C2C12 (myoblasts) |
|
Permissive
Robust
|
Mus musculus |
ENCSR000AIV
...
|
MA0466.2
|
CEBPB |
Tot2 (myeloid progenitor cell line) |
|
Permissive
Robust
|
Mus musculus |
GSE43007
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50455
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50455
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50455
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50455
...
|
MA0466.2
|
CEBPB |
hematopoietic cells |
|
Permissive
Robust
|
Mus musculus |
GSE40235
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50416
...
|
MA0466.2
|
CEBPB |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50416
...
|
MA0466.2
|
CEBPB |
BV-2 (brain microglial cells) |
|
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0466.2
|
CEBPB |
3T3-L1-derived adipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE56745
...
|
MA0466.2
|
CEBPB |
monocyte-derived dendritic cells |
|
Permissive
Robust
|
Mus musculus |
GSE62702
...
|
MA0466.2
|
CEBPB |
plasmacytoid dendritic cells |
|
Permissive
Robust
|
Mus musculus |
GSE62702
...
|
MA0466.2
|
CEBPB |
acute myeloid leukemia |
|
Permissive
Robust
|
Mus musculus |
GSE66122
...
|
MA0466.2
|
CEBPB |
liver |
|
Permissive
Robust
|
Mus musculus |
GSE77670
...
|
MA0466.2
|
CEBPB |
bone marrow-derived mesenchymal stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0466.2
|
CEBPB |
Ly6Clo monocytes |
|
Permissive
Robust
|
Mus musculus |
GSE80031
...
|
MA0466.2
|
CEBPB |
Hoxb8-FL |
|
Permissive
Robust
|
Mus musculus |
GSE84328
...
|
MA0466.2
|
CEBPB |
bone marrow-derived macrophages |
|
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0466.2
|
CEBPB |
MV-4-11 (Childhood acute monocytic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE88746
...
|
MA0466.2
|
CEBPB |
embryonic fibroblasts |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0466.2
|
CEBPB |
embryonic fibroblasts expressing OSKM for 48h |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0466.2
|
CEBPB |
pre-induced pluripotent stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0466.2
|
CEBPB |
A549 (lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR701TCU
|
MA0466.2
|
CEBPB |
monocyte-derived macrophages |
|
Permissive
Robust
|
Homo sapiens |
GSE104638
...
|
MA0466.2
|
CEBPB |
HL-60 (acute myeloid leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE107553
...
|
MA0466.2
|
CEBPB |
32D |
|
Permissive
Robust
|
Mus musculus |
GSE100487
...
|
MA0466.2
|
CEBPB |
|
|
Permissive
Robust
|
Homo sapiens |
GSE66192
|
MA0466.2
|
CEBPB |
LS180 (colon cancer) |
125 |
Permissive
Robust
|
Homo sapiens |
GSE31939
|
MA0466.2
|
CEBPB |
|
DMI_HI |
Permissive
Robust
|
Homo sapiens |
GSE68864
|
MA0466.2
|
CEBPB |
|
DMI_LOW |
Permissive
Robust
|
Homo sapiens |
GSE68864
|
MA0466.2
|
CEBPB |
LS180 (colon cancer) |
|
Permissive
Robust
|
Homo sapiens |
GSE31939
|
MA0466.2
|
CEBPB |
|
|
Permissive
Robust
|
Homo sapiens |
GSE68864
|
MA0466.2
|